Quanterix announces new agreement to advance blood-based Alzheimer’s detection

Quanterix (QTRX) “announced the signing of a license agreement with Janssen Sciences Ireland UC, a Johnson & Johnson (JNJ) Company. Under this agreement, Quanterix will receive worldwide, non-exclusive rights to J&J’s extensively studied p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products, further strengthening Quanterix’s position at the forefront of the Alzheimer’s Disease biomarker field. Under the terms of the license agreement, Janssen will grant Quanterix a worldwide non-exclusive license for J&J-developed technology to produce Simoa p-Tau 217 research-use only assay kits for global distribution. Furthermore, under the agreement Quanterix will launch a Laboratory Developed Test based on the J&J p-Tau 217 antibodies and assay, offered through Accelerator under the Lucent Diagnostics brand. These advances mark a significant milestone for Quanterix’s continued leadership in advancing Alzheimer’s Disease diagnosis and treatment, providing a path for the first scalable immunoassay-based p-Tau 217 test to potentially become widely available to researchers and clinicians.”